Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synmosa BiopharmaROCO:4114 +3.31%83 Return-on-Tangible-Asset is 5.65% as of Mar. 2026, which is 1% below its 10-year median of 5.71. GuruFocus rates ROCO:4114 with a GF Score™ of 83/100 and a GF Value™ of NT$33.03 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,006 Drug Manufacturers companies, Synmosa Biopharma ranks better than 63.22% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Synmosa Biopharma's annualizedNet Income for the quarter that ended in Mar. 2026 was NT$767 Mil. Synmosa Biopharma's average total tangible assets for the quarter that ended in Mar. 2026 was NT$13,583 Mil. Therefore, Synmosa Biopharma's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 5.65%.
The historical rank and industry rank for Synmosa Biopharma's Return-on-Tangible-Asset or its related term are showing as below:
ROCO:4114'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 0.07 Med: 5.71 Max: 7.82
Current: 5.97
During the past 13 years, Synmosa Biopharma's highest Return-on-Tangible-Asset was 7.82%. The lowest was 0.07%. And the median was 5.71%.
ROCO:4114's Return-on-Tangible-Asset is ranked better than 63.22% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 3.05
vs ROCO:4114: 5.97
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Synmosa Biopharma Return-on-Tangible-Asset Related Terms
Synmosa Biopharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Synmosa Biopharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4114 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synmosa Biopharma Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Synmosa Biopharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 5.65% mean?
Synmosa Biopharma (ROCO:4114) has a Return-on-Tangible-Asset of 5.65% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Synmosa Biopharma and its competitors. This is near median its historical median of 5.71. Over the past decade, Synmosa Biopharma's Return-on-Tangible-Asset has ranged from 0.07 to 7.82. According to the industry distribution chart, Synmosa Biopharma ranks #370 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 36.8%.
Is Synmosa Biopharma's Return-on-Tangible-Asset too high?
Synmosa Biopharma's current Return-on-Tangible-Asset of 5.65% is near median its 10-year median of 5.71. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 7.82. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.05. Synmosa Biopharma's value of 5.65% is 85.2% above this industry median. Based on the distribution chart, Synmosa Biopharma ranks #370 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Synmosa Biopharma has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Synmosa Biopharma ranks #370 out of 1006 companies for Return-on-Tangible-Asset. This puts Synmosa Biopharma in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.05. Synmosa Biopharma's value of 5.65% is 85.2% above this benchmark. Historically, Synmosa Biopharma's own Return-on-Tangible-Asset has ranged from 0.07 to 7.82 over the past decade. While the company's 10-year median is 5.71 vs. the industry median of 3.05, Synmosa Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.05, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synmosa Biopharma's current Return-on-Tangible-Asset of 5.65% is 85.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Synmosa Biopharma and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synmosa Biopharma's current Return-on-Tangible-Asset is 5.65%, which is near median its own 10-year median of 5.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.03, compared to a current price of NT$31.25 — trading 5.4% below its estimated fair value. The current Return-on-Tangible-Asset is 5.65%, which is near median its 10-year median of 5.71 and 85.2% above the Drug Manufacturers industry median of 3.05. Synmosa Biopharma's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current Return-on-Tangible-Asset is 5.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?
Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued.
The current stock price of NT$31.25 is trading 5.4% below its estimated GF Value™ of NT$33.03.
GuruFocus considers Synmosa Biopharma to be Fairly Valued.
Key valuation signals for ROCO:4114:
Return-on-Tangible-Asset: 5.65% (near median its 10-year median of 5.71)
GF Value™: NT$33.03 vs. price of NT$31.25 (5.4% below fair value)
Industry Position: 85.2% above the Drug Manufacturers median (#370 of 1006)
No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
83GF Score
Get the complete analysis for ROCO:4114
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4114 has been successfully added to your 
